首页 | 本学科首页   官方微博 | 高级检索  
检索        

盐酸二甲双胍缓释片的生物等效性评价
引用本文:吴琳华,刘红梅,赵红光,纪宏宇,王智勇,杜霞.盐酸二甲双胍缓释片的生物等效性评价[J].中国药学杂志,2006,41(3):214-216.
作者姓名:吴琳华  刘红梅  赵红光  纪宏宇  王智勇  杜霞
作者单位:哈尔滨医科大学附属第二医院药学部,哈尔滨,150086
摘    要: 目的对国产两种盐酸二甲双胍缓释片制剂进行生物等效性评价。方法单剂量(1 000 mg)、多剂量(1 000 mg·d-1×7d)试验各选20例受试者,受试者随机分组、自身对照口服药物,采用反相HPLC测定血浆中盐酸二甲双胍的浓度,并计算相关药动学参数判定两制剂是否生物等效。结果单剂量时,受试制剂与参比制剂主要药动学参数ρmax分别为(2.329±0.486)及(2.308±0.502)mg·L-1;tmax分别为(3.700±0.571)及(3.600±0.940)h;t1/2分别为(7.484±2.612)及(7.724±2.799)h;AUC0~t分别为(13.387±3.394)及(13.589±2.917)mg·h·L-1;AUC0~∞分别为(18.575±3.841)及(19.069±3.792)mg·h·L-1;受试制剂相对于参比制剂的生物利用度F为(98.10±8.90)%。多剂量时,受试制剂与参比制剂主要药动学参数ρmax分别为(1.876±0.545)及(2.111±0.630)mg·L-1;ρmin分别为(0.212±0.047)及(0.227±0.054)mg·L-1;tmax分别为(4.100±0.912)及(3.750±0.716)h;t1/2分别为(11.477±3.851)及(13.529±4.067)h;AUCss分别为(15.137±2.749)及(15.855±3.322)mg·h·L-1;ρav分别为(0.631±0.114)及(0.661±0.138)mg·L-1;DF分别为(2.609±0.644)%及(2.812±0.645)%;受试制剂相对于参比制剂的生物利用度F为(98.00±22.7)%。结论统计分析结果显示,受试制剂与参比制剂生物等效。

关 键 词:盐酸二甲双胍  反相高效液相色谱法  药动学  生物等效性
文章编号:1001-2494(2006)03-0214-03
收稿时间:2005-01-26
修稿时间:2005-01-26

Studies on Bioequivalence of Metformin Hydrochloride Sustained Release Tablets
WU Lin-hua,LIU Hong-mei,ZHAO Hong-guang,JI Hong-yu,WANG Zhi-yong,DU Xia.Studies on Bioequivalence of Metformin Hydrochloride Sustained Release Tablets[J].Chinese Pharmaceutical Journal,2006,41(3):214-216.
Authors:WU Lin-hua  LIU Hong-mei  ZHAO Hong-guang  JI Hong-yu  WANG Zhi-yong  DU Xia
Institution:Department of Pharmacy,Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
Abstract:OBJECTIVE To study the bioequivalence of metformin hydrochloride tablets in healthy volunteers.METHODS A single oral dose(1 000 mg) and multiple oral doses(1 000 mg·d-1×7 d) of reference or test metformin hydrochloride preparations were given to 20 healthy male volunteers according to an open randomized crossover study.The plasma concentrations of metformin hydrochloride were determined by RP-HPLC method.The pharmacokinetic parameters and bioavailability of test preparation were compared with reference preparation.RESULTS The main pharmacokinetic parameters of the test preparation and the reference preparation were as follows,single dose(SD): ρmax(2.329±0.486) and(2.308±0.502) mg·L-1;tmax(3.700±0.571) and(3.600±0.940)h;t1/2(7.484±2.612) and(7.724±2.799)h;AUC0~t(13.387±3.394) and(13.589±2.917) mg·h·L-1;AUC0~∞(18.575±3.841) and(19.069±3.792) mg·h·L-1.The relative bioavailability of the test to reference preparation was(98.10±8.90)%.Multiple doses(MD): ρmax(1.876±0.545) and(2.111±0.630) mg·L-1;ρmin(0.212±0.047) and(0.227±0.054)mg·L-1;tmax(4.100±0.912) and(3.750±0.716)h;t1/2((11.477±3.851))and(13.529±4.067) h;AUCss(15.137±2.749) and(15.855±3.322) mg·h·L-1;ρav(0.631±0.114) and((0.661±0.138)) mg·L-1;DF(2.609±0.644)% and(2.812±0.645)%,respectively.The relative bioavailability of test to reference preparation was(98.00±22.7)%.CONCLUSION The results of statistic analysis show that the reference preparation and the test preparation are bioequivalent.
Keywords:metformin hydrochloride  RP-HPLC  pharmacokinetics  bioequivalence  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号